Evaxion(EVAX)
搜索文档
Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01
Newsfilter· 2025-01-15 13:00
Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now completed the dosing of all 16 patients in its phase 2 trial with the company's lead asset EVX-01. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advanced melanoma (s ...
Evaxion announces completion of ADS ratio change
GlobeNewswire· 2025-01-14 21:05
公司公告 - Evaxion Biotech A/S宣布其美国存托股票(ADS)与普通股的比率变更已生效 新的ADS比率为1 ADS代表50普通股 此前为1 ADS代表10普通股 [1][2] - ADS比率变更于2025年1月14日生效 对ADS持有人而言 该变更相当于1比5的反向ADS拆分 旨在进一步提高公司ADS的流动性 [2] - 在生效日 每5个现有ADS自动兑换为1个新ADS 现有ADS被取消 新ADS由存托银行纽约梅隆银行发行 [3] - 持有实物ADS的注册持有人需将实物ADS交存至存托银行以取消 并每5个现有ADS兑换1个新ADS 持有非实物ADS的持有人其ADS被自动取消并兑换 每5个现有ADS兑换1个新ADS [4] - ADS比率变更对所有股东一视同仁 不会改变任何股东在公司股本中的百分比权益 除非比率变更导致股东拥有零碎ADS 不会发行零碎新ADS 零碎ADS权益将由存托银行汇总出售 扣除费用、税款和开支后的净现金收益将分配给适用的ADS持有人 [4] - 由于ADS比率变更 ADS交易价格预计将按比例上涨 但公司无法保证变更后的ADS交易价格将与变更前的ADS交易价格成比例或更高 也无法保证比率变更会对公司ADS的流动性产生任何影响 [5] 公司介绍 - Evaxion Biotech A/S是一家基于AI-Immunology™平台的TechBio公司 利用人工智能解码人类免疫系统 开发针对癌症、细菌性疾病和病毒感染的新型免疫疗法 [6] - 基于AI-Immunology™平台 公司已开发出临床阶段的个性化肿瘤疫苗管线 以及针对高未满足医疗需求的细菌和病毒性疾病的临床前传染病管线 [6]
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
GlobeNewswire· 2025-01-10 13:00
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it is amending the effective date for its plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS ratio”), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary sha ...
Evaxion announces plan to implement ADS ratio change
Newsfilter· 2024-12-30 13:00
COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, DKK 1 nominal value (the "ADS ratio"), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the "ADS ratio change"). The ADS r ...
Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity
Newsfilter· 2024-12-17 13:00
Evaxion and the European Investment Bank (EIB) are in advanced discussions about conversion of €3.5 million out of Evaxion's €7 million loan with EIB into an equity-type instrumentSuch conversion is expected to increase Evaxion's equity by $3.7 million immediately upon completionThe conversion would significantly enhance Evaxion's equity and capital structure. As such, it is an important part of Evaxion's plan on ensuring ongoing compliance with the Nasdaq listing requirements An agreement is expected to be ...
Evaxion announces business update and third quarter 2024 financial results
GlobeNewswire News Room· 2024-10-31 12:00
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results. Business highlights (since last quarterly update) Since the second quarter 2024 business update, we have continued to execute strongly on our strategy and plans with several major milestones achieved. Key highlights include: Significant expansion of the ...
Evaxion to announce business update and third quarter 2024 financial results on October 31
GlobeNewswire News Room· 2024-10-28 12:00
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is ...
Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials
GlobeNewswire News Room· 2024-10-09 12:00
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked AI-Immunology™ vaccine targets, thereby linking AI-vaccine design with real-world evidence This underscores the platform's unique potential in selecting effective vaccine targets The ongoing generation of relevant clinical data allows for continuous refinement of AIImmunology™ thereby broadening the commercial po ...
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
GlobeNewswire News Room· 2024-10-03 12:00
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through iterative learning and the integration of advanced bioinformatics and machine learning techniques In the ongoing phase 2 trial with personalized cancer vaccine EVX-01, 79% of the AIImmunology™ predicted vaccine targets triggered a tumor-specific immune response, a significant increase from 58% observed in the E ...
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
GlobeNewswire News Room· 2024-09-19 12:00
The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction feature The launch will expectedly improve Evaxion's ability to fast and effectively discover AI-derived novel vaccines and is expected to further solidify the strong interest seen in AI-Immunology™ from potential partners New data demonstrating the improved performance of EDEN™ will be presented today at the European Conference on Computational Bi ...